Deutsch English
← back to archive
Geopolitics & Diplomacy · 615 words · MN-260603-0032

Canada Approves Generic Ozempic, Leaving US Patients

Waiting for Years

Canada has become the first G7 country to approve a generic version of the popular drug Ozempic, offering a lifeline to patients who have struggled with steep costs. Meanwhile, Americans face a much longer wait due to patent laws that protect pharmaceutical monopolies.

For Elizabeth Doran, a 69-year-old retired teacher from Ottawa, the monthly cost of her Wegovy prescription was a heavy burden. Because she was prescribed the drug for weight loss to reverse her prediabetes rather than for diabetes itself, her insurance did not cover it. Forced to pay between C$350 and C$500 out of pocket, Doran picked up substitute teaching shifts just to afford the medication. Esther Linetsky, another Canadian patient, had to temporarily stop using Ozempic and ration free samples from her doctor because the cost was too high. However, relief is now in sight for Canadians. In May, Canada approved a generic semaglutide injection—manufactured by India-based Dr Reddy's and Canadian company Apotex—that will be available in pharmacies by early June for less than a third of the original price. The arrival of these generics has already forced the brand's manufacturer, Novo Nordisk, to lower the prices of its name-brand drugs.

The situation is drastically different in the United States, where uninsured patients pay upwards of US$1,000 a month for Ozempic. Experts say low-cost alternatives will not reach the US market for several years. Tahir Amin, CEO of the Initiative for Medicines, Access & Knowledge (I-MAK), explained that US and European laws allow companies to extend their patents for years to compensate for regulatory delays. Consequently, Americans will likely not see a generic version until 2032, when the main compound patent for semaglutide expires. Amin noted that the high prices mean GLP-1 drugs are mostly accessible to the wealthy, while those who need them to manage diabetes are left struggling. He called the US patent system the "Golden Egg" of the pharmaceutical industry, which has aggressively lobbied to maintain the status quo. Novo Nordisk recently demonstrated this stance by taking US online pharmacy Hims and Hers to court for selling compounded versions of semaglutide at a lower cost. The legal battle was dropped in March only after the pharmacy agreed to stop advertising the compounds.

The reason Canadians have access to generics sooner is due to a missed deadline by the manufacturer. Novo Nordisk could have extended its patent in Canada until 2028, but the company failed to renew it. Amin remarked that "somebody dropped the ball," paving the way for generics. In a statement, Novo Nordisk described the introduction of generics in Canada as a "localized situation based on our specific patent timelines and regulatory environment" that does not reflect the situation in the United States, where exclusivity remains intact.

Despite the tentative FDA approval secured by Apotex for its generic drug, CEO Martin Arès said it will definitely not hit the US market this year, though his team is exploring ways to bring it to Americans as soon as possible. Meanwhile, Amin anticipates that Americans are already looking north for access to low-cost generic Ozempic. This would not be unprecedented: in 2019, a caravan of Americans bused to Canada to buy cheaper insulin. More recently, in 2023, the Canadian province of British Columbia restricted Americans from purchasing Ozempic after finding that 15% of the drug's prescriptions were going to the US, mostly through Canadian online pharmacies. British Columbia's then-health minister, Adrian Dix, strongly condemned the practice, stating the drug was intended for local patients, not for export back to the United States.